Salud financiera de hoja de balance de Nordic Nanovector

Salud financiera controles de criterios 4/6

Nordic Nanovector tiene un patrimonio de los accionistas total de NOK63.8M y una deuda total de NOK0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son NOK109.6M y NOK45.8M respectivamente.

Información clave

Ratio deuda-patrimonio

NOK 0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	NOK 98.72m
Patrimonio	NOK 63.84m
Total pasivo	NOK 45.80m
Activos totales	NOK 109.65m

Actualizaciones recientes sobre salud financiera

Recent updates

Can Nordic Nanovector (OB:NANOV) Afford To Invest In Growth?

Aug 30

Is Nordic Nanovector (OB:NANOV) In A Good Position To Invest In Growth?

Nov 09

We Think Nordic Nanovector (OB:NANOV) Needs To Drive Business Growth Carefully

Jul 02

Is Nordic Nanovector (OB:NANOV) In A Good Position To Invest In Growth?

Jan 06

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (NOK109.1M) de NANOV superan a sus pasivos a corto plazo (NOK44.3M).

Pasivo a largo plazo: Los activos a corto plazo de NANOV (NOK109.1M) superan a sus pasivos a largo plazo (NOK1.5M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: NANOV está libre de deudas.

Reducción de la deuda: NANOV no ha tenido ninguna deuda en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: NANOV tiene menos de un año de cash runway basado en su flujo de caja libre actual.

Pronóstico de cash runway: NANOV tiene menos de un año de cash runway si el flujo de caja libre sigue reduciéndose a tasas históricas de 10.2% cada año

Salud financiera de hoja de balance de Nordic Nanovector

Salud financiera controles de criterios 4/6

Información clave

Actualizaciones recientes sobre salud financiera

Can Nordic Nanovector (OB:NANOV) Afford To Invest In Growth?

Is Nordic Nanovector (OB:NANOV) In A Good Position To Invest In Growth?

We Think Nordic Nanovector (OB:NANOV) Needs To Drive Business Growth Carefully

Is Nordic Nanovector (OB:NANOV) In A Good Position To Invest In Growth?

Recent updates

Nordic Nanovector ASA Approves the Appointment of Ludvik Sandnes as New Chairman

Nordic Nanovector ASA Announces Resignation of Jostein Dahle, Chief Scientific Officer and Co-Founder

Chairperson recently bought kr436k worth of stock

New major risk - Share price stability

Nordic Nanovector ASA Announces CFO Changes

Nordic Nanovector ASA Announces Resignation of Eddie Berglund from the Board Effect from January 19, 2023

No independent directors

Nordic Nanovector ASA Approves Board Changes

Nordic Nanovector ASA to Report First Half, 2023 Results on Aug 31, 2023

Nordic Nanovector ASA (OB:NANOV) agreed to acquire 100% stake in APIM Therapeutics AS from Sarsia Seed AS, Trond Mohn Stiftelsen, Norsk Innovasjonskapital (NIK) III Fund, and Investinor Direkte AS.

Nordic Nanovector ASA Announces Resignation of Solveig Hellebust, Jean Pierre Bizzari and Thomas Ramdahl from the Board

Can Nordic Nanovector (OB:NANOV) Afford To Invest In Growth?

Nordic Nanovector ASA Announces Executive Changes

Nordic Nanovector ASA to Report Q2, 2022 Results on Aug 31, 2022

Nordic Nanovector to Seek Regulatory Feedback Following Its Preliminary Review and Independent Data Evaluation of Paradigme, Its Phase 2B Trial with Betalutin in R/R Follicular Lymphoma

Nordic Nanovector ASA Provides an Update on PARADIGME, Its Phase 2b trial of Betalutin in R/R FL as a Result of Continuing Slow Recruitment

Nordic Nanovector ASA Publishes Highlights Synergistic Potential of CD37-Targeted Radioimmunoconjugate Humalutin

Price target decreased to kr26.00

Price target decreased to kr26.00

Insufficient new directors

Price target increased to kr31.00

Nordic Nanovector ASA Provides an Update on the Timeline for PARADIGME

Is Nordic Nanovector (OB:NANOV) In A Good Position To Invest In Growth?

Price target decreased to kr27.25

Nordic Nanovector ASA Provides Update on Paradigme, Its Phase 2B Pivotal Trial with Betalutin® in R/R Follicular Lymphoma

Chief Executive Officer Peter Braun has left the company

We Think Nordic Nanovector (OB:NANOV) Needs To Drive Business Growth Carefully

Nordic Nanovector Announces Initial Results from LYMRIT 37-05 Phase 1 Trial of Betalutin® in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Nordic Nanovector ASA Announces Update from Archer-1 Phase 1B Trial of Betalutin® in Combination with Rituximab in 2L Follicular Lymphoma

Independent Director has left the company

Nordic Nanovector ASA Appoints Peter L. Braun as Chief Executive Officer, Effective 6 April 2021

Price target raised to kr28.25

Nordic Nanovector ASA Sees Significant Improvement in Patient Recruitment Rate in PARADIGME, its Single-Arm Phase 2 Pivotal Trial with Betalutin in R/R Follicular Lymphoma

New 90-day high: kr20.00

Nordic Nanovector ASA to Report Fiscal Year 2020 Results on Mar 27, 2021

Is Nordic Nanovector (OB:NANOV) In A Good Position To Invest In Growth?

Nordic Nanovector ASA to Report Q2, 2021 Results on Aug 27, 2021

Nordic Nanovector ASA Completes Patient Enrolment into Phase 1 Trial of Betalutin® in Diffuse Large B Cell Lymphoma

Price target lowered to kr21.00

Price target lowered to kr38.50

Nordic Nanovector ASA Completes Enrolment into Second Safety Cohort of Follicular Lymphoma Patients in Archer-1 Phase 1B Betalutin®/Rituximab Combination Trial

New 90-day low: kr14.85

Nordic Nanovector Asa Publishes Results of Preclinical Study Demonstrating Betalutin Reverses Tumour Resistance to Rituximab in NHL Disease Models

New 90-day low: kr16.83

Nordic Nanovector Launches A -2-Haematogical L Cancers

New 90-day high - kr27.90

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera